The Family Firm’s Zimmer Biomet ZBH Stock Holding History

The Family Firm’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-307	Closed	-$33.3K	–	867
2024 Q2	$33.3K	Buy	+307	New	+$36.2K	0.01%	486

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

The Family Firm's ZBH Position: Q3 2024 in Review

The Family Firm sold out of Zimmer Biomet (ZBH) in Q3 2024, closing a stake of 307 shares — an estimated $33.3K sold.

The Family Firm first reported a position in ZBH in Q2 2024 and held it in 1 quarter. The position peaked at $33.3K in Q2 2024. 982 funds tracked by Wall St. Rank hold ZBH as of Q3 2024.

The Family Firm reported no remaining Zimmer Biomet position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 307 Zimmer Biomet shares in Q3 2024, an estimated $33.3K.
The Family Firm first reported a position in Zimmer Biomet in Q2 2024 and held it in 1 quarter.
The Family Firm's Zimmer Biomet position peaked at $33.3K in Q2 2024.
982 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.